← Back to Search

Iodine-124 Imaging for Thyroid Cancer

Phase 1

Recruiting

Led By Ravinder Grewal, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adults with thyroid carcinoma confirmed by pathology

Adult thyroid carcinoma patients who have undergone total thyroidectomy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial is testing a new way to image radioactivity in cancer to see if it can better predict if a cancer will respond to radioiodine therapy.

Who is the study for?

This trial is for adults with confirmed thyroid carcinoma who've had their thyroid removed and either have metastatic disease or are suspected to. They should be planning on radioiodine therapy if persistent cancer that absorbs iodine is found, and must have measurable disease documented in the last six months.Check my eligibility

What is being tested?

The study tests a new PET scan using radioactive iodine-124 to see how much iodine the cancer takes up. This helps decide if standard radioiodine therapy will work or if another treatment is better. The test could lead to continuing usual treatment or switching strategies based on uptake levels.See study design

What are the potential side effects?

Since this trial focuses on diagnostic imaging rather than a therapeutic intervention, side effects may include discomfort from the PET/CT procedure, potential allergic reactions to contrast agents used during imaging, and exposure to radiation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My thyroid cancer diagnosis is confirmed by a pathology report.

Select...

I had my entire thyroid removed due to cancer.

Select...

I am considering 131I therapy for my thyroid cancer metastases.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

number of individual lesions response

Trial Design

1Treatment groups

Experimental Treatment

Group I: Lesion Dosimetry With Iodine-124Experimental Treatment2 Interventions

Patients will be administered 124I and undergo serial PET imaging consisting of up to 4 individual PET/CT scans. In order to perform a dual exponential fit, 4 scans are needed to obtain the necessary amount of data points required. Lesion dosimetry shall be performed based on the 124I PET scan data through tumor uptake and clearance pharmacokinetics. 10 patients, who sign consent for the sub-study, will be administered an additional tracer diagnostic activity of 124I (4 to 7 mCi). These patients will then undergo additional (up to a maximum of 4) PET scanning during radioiodine therapy at time points matched, if possible, to the days of the pre-therapy 124I dosimetry study.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PET/CT Scan

2013

Completed Phase 2

~1370

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,934 Previous Clinical Trials

588,744 Total Patients Enrolled

Ravinder Grewal, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

4 Previous Clinical Trials

35 Total Patients Enrolled

Media Library

PET/CT Scan Clinical Trial Eligibility Overview. Trial Name: NCT03647358 — Phase 1

Thyroid Cancer Research Study Groups: Lesion Dosimetry With Iodine-124

Thyroid Cancer Clinical Trial 2023: PET/CT Scan Highlights & Side Effects. Trial Name: NCT03647358 — Phase 1

PET/CT Scan 2023 Treatment Timeline for Medical Study. Trial Name: NCT03647358 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any risks to undergoing a PET/CT scan?

"Due to the limited clinical data available, PET/CT Scan was assigned a score of 1 on our safety scale. As this is only Phase 1 testing, there has not been much evidence put forth regarding its efficacy or safety."

Answered by AI

Are there vacancies available for participants in this research endeavor?

"The information on clinicaltrials.gov attests to this trial's ongoing recruitment of patients, which began in August 2018 and was most recently updated at the start of August 2022."

Answered by AI

How many people will be incorporated into this medical experiment?

"Affirmative, the information posted on clinicaltrials.gov indicates that this medical trial is currently accepting applicants. It was first announced on August 21st 2018 and last updated 8/1/2022, with a total of 60 patients being sought from two different sites."

Answered by AI

Has the combination of PET/CT Scan been subject to any prior research?

"Currently, 15 clinical trials are being conducted to evaluate PET/CT Scan. Two of those studies have reached Phase 3 status and 37 different locations across the world are participating in these experiments. The majority of these tests are taking place near North Adelaide, South Australia."

Answered by AI